Network Pharmacology-Oriented Identification of Key Proteins and Signaling Pathways Targeted by Xihuang Pill in the Treatment of Breast Cancer

References

• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• NarodSA, IqbalJ, MillerAB. Why have breast cancer mortality rates declined?J Cancer Policy. 2015;5:8–17. doi:10.1016/j.jcpo.2015.03.002
   Google Scholar
• MehlenP, PuisieuxA. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6(6):449–458.16723991
   PubMed Web of Science ®Google Scholar
• MonteiroJ, FoddeR. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer. 2010;46(7):1198–1203. doi:10.1016/j.ejca.2010.02.03020303259
   PubMed Web of Science ®Google Scholar
• GuanX. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402–418.26579471
   PubMed Web of Science ®Google Scholar
• DeshmukhSK, SrivastavaSK, TyagiN, et al. Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: a closer look at the surroundings. Carcinogenesis. 2017;38(8):757–765. doi:10.1093/carcin/bgx03728430867
   PubMed Web of Science ®Google Scholar
• DeshmukhSK, SrivastavaSK, PoosarlaT, et al. Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy. Ann Transl Med. 2019;7(20):593. doi:10.21037/atm.2019.09.6831807574
   PubMed Web of Science ®Google Scholar
• ZahidH, SimpsonER, BrownKA. Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer. Curr Opin Pharmacol. 2016;31:90–96. doi:10.1016/j.coph.2016.11.00327875786
   PubMed Web of Science ®Google Scholar
• PanG, WangW, WangL, et al. Anti-breast cancer effects and mechanisms of Xihuang pill on human breast cancer cell lines. J Tradit Chin Med. 2013;33(6):770–778. doi:10.1016/S0254-6272(14)60011-X24660610
   PubMed Web of Science ®Google Scholar
• MaoD, FengL, HuangS, ZhangS, PengW, ZhangS. Meta-analysis of Xihuang pill efficacy when combined with chemotherapy for treatment of breast cancer. Evid Based Complement Alternat Med. 2019;2019:3502460. doi:10.1155/2019/350246030992708
   PubMed Web of Science ®Google Scholar
• ZhengW, HanS, JiangS, et al. Multiple effects of Xihuang pill aqueous extract on the Hs578T triple-negative breast cancer cell line. Biomed Rep. 2016;5(5):559–566. doi:10.3892/br.2016.76927882217
   PubMedGoogle Scholar
• HeLJ, LiJS, ChenX, et al. [Effect of serum containing Xihuang pill on proliferation of human breast cancer cell line MDA-MB-435 and MCF-7 cells]. Zhongguo Zhong Yao Za Zhi. 2018;43(13):2784–2788. Chinese.30111032
   PubMedGoogle Scholar
• GuoQ, LinJ, LiuR, et al. Review on the applications and molecular mechanisms of Xihuang pill in tumor treatment. Evid Based Complement Alternat Med. 2015;2015:854307. doi:10.1155/2015/85430726170886
   PubMed Web of Science ®Google Scholar
• ShannonP, MarkielA, OzierO, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.123930314597658
   PubMed Web of Science ®Google Scholar
• ChinCH, ChenSH, WuHH, HoCW, KoMT, LinCY. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. doi:10.1186/1752-0509-8-S4-S1125521941
   PubMed Web of Science ®Google Scholar
• LuoH, VongCT, ChenH, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med. 2019;14:48.31719837
   PubMed Web of Science ®Google Scholar
• XiaoE, LuoL. Alternative therapies for diabetes: a comparison of western and Traditional Chinese Medicine (TCM) approaches. Curr Diabetes Rev. 2018;14(6):487–496. doi:10.2174/157339981366617051910323028523995
   PubMed Web of Science ®Google Scholar
• LiuT, DingY, WenA. Traditional Chinese medicine for ischaemic stroke. Lancet Neurol. 2018;17(9):745. doi:10.1016/S1474-4422(18)30290-4
   PubMedGoogle Scholar
• TangK-Y, DuS-L, WangQ-L, ZhangY-F, SongH-Y. Traditional Chinese medicine targeting cancer stem cells as an alternative treatment for hepatocellular carcinoma. J Integr Med. 2020;18:196–202. doi:10.1016/j.joim.2020.02.00232067923
   PubMed Web of Science ®Google Scholar
• YanZ, LaiZ, LinJ. Anticancer properties of traditional Chinese medicine. Comb Chem High Throughput Screen. 2017;20(5):423–429. doi:10.2174/138620732066617011614181828093974
   PubMed Web of Science ®Google Scholar
• QiFH, ZhaoL, ZhouAY, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015;9(1):16–34. doi:10.5582/bst.2015.0101925787906
   PubMed Web of Science ®Google Scholar
• TaoWW, JiangH, TaoXM, JiangP, ShaLY, SunXC. Effects of Acupuncture, Tuina, Tai Chi, Qigong, and traditional Chinese medicine five-element music therapy on symptom management and quality of life for cancer patients: a meta-analysis. J Pain Symptom Manage. 2016;51(4):728–747. doi:10.1016/j.jpainsymman.2015.11.02726880252
   PubMed Web of Science ®Google Scholar
• LiaoYH, LiCI, LinCC, LinJG, ChiangJH, LiTC. Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J Cancer Res Clin Oncol. 2017;143(12):2425–2435. doi:10.1007/s00432-017-2491-628803328
   PubMed Web of Science ®Google Scholar
• MinDY, JungE, KimJ, LeeYH, ShinSY. Leptin stimulates IGF-1 transcription by activating AP-1 in human breast cancer cells. BMB Rep. 2019;52(6):385–390. doi:10.5483/BMBRep.2019.52.6.18930293548
   PubMed Web of Science ®Google Scholar
• XuJ, ChenY, OlopadeOI. MYC and breast cancer. Genes Cancer. 2010;1(6):629–640. doi:10.1177/194760191037869121779462
   PubMedGoogle Scholar
• SuL, JiangY, XuY, et al. Xihuang pill promotes apoptosis of Treg cells in the tumor microenvironment in 4T1 mouse breast cancer by upregulating MEKK1/SEK1/JNK1/AP-1 pathway. Biomed Pharmacother. 2018;102:1111–1119. doi:10.1016/j.biopha.2018.03.06329710529
   PubMed Web of Science ®Google Scholar
• ChenG, DingXF, PressleyK, et al. Everolimus inhibits the progression of ductal carcinoma in situ to invasive breast cancer via downregulation of MMP9 expression. Clin Cancer Res. 2019.
   Web of Science ®Google Scholar
• RodriguesS, BruyneelE, RodrigueCM, ShahinE, GespachC. [Cyclooxygenase 2 and carcinogenesis]. Bull Cancer. 2004;91(Suppl 2):S61–76. French.
   Google Scholar
• TongD, LiuQ, WangLA, et al. The roles of the COX2/PGE2/EP axis in therapeutic resistance. Cancer Metastasis Rev. 2018;37(2–3):355–368. doi:10.1007/s10555-018-9752-y30094570
   PubMed Web of Science ®Google Scholar
• BosPD, ZhangXHF, NadalC, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005–1009. doi:10.1038/nature0802119421193
   PubMed Web of Science ®Google Scholar
• NandiP, GirishGV, MajumderM, XinX, Tutunea-FatanE, LalaPK. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. BMC Cancer. 2017;17(1):11. doi:10.1186/s12885-016-3018-228056899
   PubMed Web of Science ®Google Scholar
• KochelTJ, ReaderJC, MaX, KunduN, FultonAM. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer. Oncotarget. 2017;8(4):6540–6554. doi:10.18632/oncotarget.1414528029661
   PubMedGoogle Scholar
• LiS, WeiX, HeJ, TianX, YuanS, SunL. Plasminogen activator inhibitor-1 in cancer research. Biomed Pharmacother. 2018;105:83–94. doi:10.1016/j.biopha.2018.05.11929852393
   PubMed Web of Science ®Google Scholar
• DuffyMJ, McGowanPM, HarbeckN, ThomssenC, SchmittM. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014;16(4):428. doi:10.1186/s13058-014-0428-425677449
   PubMed Web of Science ®Google Scholar
• BhateliaK, SinghK, SinghR. TLRs: linking inflammation and breast cancer. Cell Signal. 2014;26(11):2350–2357. doi:10.1016/j.cellsig.2014.07.03525093807
   PubMed Web of Science ®Google Scholar
• ChowMT, LusterAD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–1131. doi:10.1158/2326-6066.CIR-14-016025480554
   PubMed Web of Science ®Google Scholar
• ChangSH. T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Arch Pharm Res. 2019;42(7):549–559. doi:10.1007/s12272-019-01146-930941641
   PubMed Web of Science ®Google Scholar
• SongY, YangJM. Role of interleukin (IL)-17 and T-helper (Th)17 cells in cancer. Biochem Biophys Res Commun. 2017;493(1):1–8. doi:10.1016/j.bbrc.2017.08.10928859982
   PubMed Web of Science ®Google Scholar
• LimKH, StaudtLM. Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 2013;5(1):a011247. doi:10.1101/cshperspect.a01124723284045
   PubMed Web of Science ®Google Scholar
• EchizenK, HiroseO, MaedaY, OshimaM. Inflammation in gastric cancer: interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. Cancer Sci. 2016;107(4):391–397. doi:10.1111/cas.1290127079437
   PubMed Web of Science ®Google Scholar
• JavaidN, ChoiS. Toll-like receptors from the perspective of cancer treatment. Cancers (Basel). 2020;12(2):297. doi:10.3390/cancers12020297
   Web of Science ®Google Scholar
• van HorssenR, Ten HagenTL, EggermontAM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11(4):397–408.16614236
   PubMed Web of Science ®Google Scholar
• CruceriuD, BaldasiciO, BalacescuO, Berindan-NeagoeI. The dual role of tumor necrosis factor-alpha (TNF-alpha) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr). 2020;43(1):1–18. doi:10.1007/s13402-019-00489-131900901
   PubMed Web of Science ®Google Scholar
• PleC, FanY, Ait YahiaS, et al. Polycyclic aromatic hydrocarbons reciprocally regulate IL-22 and IL-17 cytokines in peripheral blood mononuclear cells from both healthy and asthmatic subjects. PLoS One. 2015;10(4):e0122372. doi:10.1371/journal.pone.012237225860963
   PubMed Web of Science ®Google Scholar
• RyuH, ChungY. Regulation of IL-17 in atherosclerosis and related autoimmunity. Cytokine. 2015;74(2):219–227. doi:10.1016/j.cyto.2015.03.00925890878
   PubMed Web of Science ®Google Scholar
• QianXL, XuP, ZhangYQ, et al. Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2020;180:311–319. doi:10.1007/s10549-020-05540-631993861
   PubMed Web of Science ®Google Scholar
• MogensenTH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240–273, Table of Contents.19366914
   PubMed Web of Science ®Google Scholar
• SchwartzAL, DickersonE, DagiaN, MalgorR, McCallKD. TLR signaling inhibitor, phenylmethimazole, in combination with tamoxifen inhibits human breast cancer cell viability and migration. Oncotarget. 2017;8(69):113295–113302. doi:10.18632/oncotarget.1035829371911
   PubMedGoogle Scholar
• XuM, LiD, YangC, JiJS. MicroRNA-34a inhibition of the TLR signaling pathway via CXCL10 suppresses breast cancer cell invasion and migration. Cell Physiol Biochem. 2018;46(3):1286–1304. doi:10.1159/00048911129689563
   PubMedGoogle Scholar
• ZhangZ, LinG, YanY, et al. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells. Oncogene. 2018;37(25):3456–3470. doi:10.1038/s41388-018-0221-429559745
   PubMed Web of Science ®Google Scholar
• MaY, RenY, DaiZJ, WuCJ, JiYH, XuJ. IL-6, IL-8 and TNF-alpha levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med. 2017;26(3):421–426. doi:10.17219/acem/6212028791816
   PubMed Web of Science ®Google Scholar